Pancreatic epithelial fluid and bicarbonate secretion is significantly elevated in the absence of peripheral serotonin

We read the manuscript by Sonda et al1 recently published in Gut with great interest. The authors elegantly demonstrated that lack of peripheral serotonin (5-HT) in tryptophan hydroxylase 1 knockout (TPH1–/–) mice remarkably limited pancreatic damage and leucocyte infiltration during the early phase of cerulein-induced acute pancreatitis (AP) and identified 5-HT as an important regulator of zymogen secretion in acinar cells. Although the study was very comprehensive, the ductal function of TPH1–/– mice was not investigated, which might be another key player in this protection. Notably, 5-HT was shown to inhibit fluid and HCO3– secretion of pancreatic ductal epithelial cells,2 which play a pivotal role in pancreatic physiology and can influence the severity of AP.3 Thus, we investigated the possible alterations of pancreatic ductal secretion in TPH1–/– mice. To achieve our aim, intralobular/interlobular pancreatic ducts were isolated from the pancreas of wild-type (TPH1+/+)...
Source: Gut - Category: Gastroenterology Authors: Tags: PostScript Source Type: research

Related Links:

Idiopathic chronic pancreatitis (ICP) is the second most common subtype of CP. In 1994, researchers reported the bimodal age at onset of ICP symptoms: early-onset ICP (EO-ICP; median age, 19.2 years) and late-onset ICP (LO-ICP; median age, 56.2 years). Ages of onset and clinical features of ICP differed from those of alcohol-related CP (ACP). However, variants in PRSS1 had not yet been associated with ICP. We reexamined ages of onset of ICP in a large, North American cohort of patients, and investigated the effects of genetic factors and alcohol use in patients with EO-ICP, LO-ICP, or ACP.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19). The University of Tokyo announced these new findings on March 18, 2020.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Authors: Yoshizawa N, Sugimoto K, Tameda M, Inagaki Y, Ikejiri M, Inoue H, Usui M, Ito M, Takei Y Abstract Despite the development of several therapeutic options, the prognosis of pancreatic cancer remains poor. One reason for this is the difficulty of diagnosing the disease at an early stage. For example, carbohydrate antigen (CA) 19-9, which is the most widely used biomarker for pancreatic cancer, cannot be used to detect the disease at early stages. Some studies have attempted to find novel biomarkers for pancreatic cancer. The aim of the present study was to find a novel diagnostic biomarker for pancreatic duct...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
AbstractPurpose of ReviewThe aim was to review evidence about diabetes secondary to hereditary pancreatitis, seeking novel diagnostic and treatment features.Recent FindingsHereditary pancreatitis (HP) is an autosomal dominant condition, characterized by recurrent episodes of acute pancreatitis, progression to fibrosis, and chronic pancreatitis. Clinical presentation includes diabetes of the exocrine pancreas (DEP). HP prevalence ranges from 0.3 to 0.57 per 100,000 people, with up to 80% of these develop DEP. This condition often requires specific interventions: with regard to metabolic control, metformin is the first choic...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
Conditions:   Trauma Injury;   Brain Injuries;   Abdominal Sepsis;   Pancreatitis;   Meningitis;   Encephalitis;   Seizures;   Acute Respiratory Distress Syndrome Interventions:   Drug: Control;   Drug: Antiseptic Solution;   Drug: Bacteriophage Sponsor:   Northern State Medical University Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pancreatitis;   Pancreas Cancer;   Pancreas Cyst Intervention:   Drug: EUS enhanced with contrast to evaluate pancreas Sponsor:   Cedars-Sinai Medical Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Trauma Injury;   Brain Injuries;   Abdominal Sepsis;   Pancreatitis;   Meningitis;   Encephalitis;   Seizures;   Acute Respiratory Distress Syndrome Interventions:   Drug: Control;   Drug: Antiseptic Solution;   Drug: Bacteriophage Sponsor:   Northern State Medical University Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pancreatitis;   Pancreas Cancer;   Pancreas Cyst Intervention:   Drug: EUS enhanced with contrast to evaluate pancreas Sponsor:   Cedars-Sinai Medical Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: In patients with early-stage nasal NKTCL, our LVD-IMRT regimen produced excellent, durable therapeutic benefit in most patients, with acceptable toxicity and no acute mortality.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Head and Neck Source Type: research
Source: Abdominal Imaging - Category: Radiology Source Type: research
More News: Gastroenterology | Pancreas | Pancreatitis | Physiology | Study